AEON Biopharma, Inc. current report, 13 July 2023

Full document

SEC Form 8-K Summary

Business Context and Reporting Period

Priveterra Acquisition Corp. filed a Form 8-K concerning its proposed business combination with AEON Biopharma, Inc. The report identifies July 13, 2023 as the earliest event date and was signed July 17, 2023.

Listing and Transaction Update

  • NYSE Regulation authorized listing of the post-combination company’s common stock and warrants on NYSE American, subject to closing of the business combination.
  • Following closing, AEON Biopharma, Inc. was expected to begin trading on July 24, 2023 under the symbols “AEON” and “AEON WS.”
  • The last expected Nasdaq trading day for Priveterra’s securities was July 21, 2023.
  • The company stated that stockholders could request withdrawal of previously submitted redemption requests until 5:00 p.m. Eastern Time on July 20, 2023.

Financial Metrics and Material Changes

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics. It also does not present a comparison with a prior period or quantify any material financial change.

Outlook, Risks, and Unusual Items

  • Completion of the business combination and the planned NYSE American listing remained subject to closing conditions.
  • The filing contains forward-looking statements regarding the transaction, listing, and future events. Actual results may differ due to risks and uncertainties.
  • Investors were directed to the risk factors and cautionary language in Priveterra’s IPO prospectus, the definitive proxy statement, the related S-4 registration statement, and subsequent SEC filings.
  • The Regulation FD disclosure and attached press release were furnished rather than filed for purposes of Exchange Act Section 18 liability and were not automatically incorporated by reference into other filings.

Key Facts to Verify

  1. Whether the business combination with AEON Biopharma closed as planned.
  2. Whether the post-combination securities began trading on NYSE American under “AEON” and “AEON WS.”
  3. The number of shares ultimately redeemed and the resulting cash available to the combined company.
  4. Any subsequent filings providing AEON’s financial condition, liquidity, operating results, and updated guidance.
  5. Transaction-related risks and conditions described in the definitive proxy statement and S-4 registration statement.